FDA grants fast-track status to Pfizer ’s tafamidis to treat TTR-CM

The US Food and Drug Administration (FDA) has granted fast-track designation to Pfizer ’s investigational candidate, tafamidis, for the treatment of patients with transthyretin cardiomyopathy (TTR-CM).
Source: Pharmaceutical Technology - Category: Pharmaceuticals Source Type: news